Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — Q2 FY2013 Earnings Presentation

14 slides from Daiichi Sankyo's earnings presentation, Nov 1, 2013

  1. Slide 1: Results Briefing: Results for 2Q FY2013

    Results Briefing Results for 2Q FY2013 (April 1 – September 30, 2013) DAIICHI SANKYO CO., LTD Joji Nakayama President and CEO November 1, 2013

  2. Slide 2: Overview 2Q YTD Results

    Overview 2Q YTD Results Consolidated Income Statement JPY Bn Ranbaxy Group Note : Figures of Ranbaxy are pre-adjusted before consolidation FY2012 2Q FY2013 2Q FY2012 FY2013 YoY (Jan-Jun) (Jan-Jun) YoY Results Results Results Results +6.7% -17.7% Net Sales 484.2 516.4 +32.2 107.7 88.6 -19.1 Cost of S

  3. Slide 3: 2Q YTD Net Sales

    2Q YTD Net Sales JPY Bn 420 440 460 480 500 520 Positive Negative Factors(+) Factors(-) FY2012 Q2 Results 484.2 Japan Nexium +19.6, Memary +3.6, Vaccines +1.8 Japan (incl. OTC) +16.5 Mevalotin -2.2 Global business ・Daiichi Sankyo Inc. (DSI) +0.9 Global Business +7.6 ・Luitpold Pharmaceuticals, Inc. (

  4. Slide 4: 2Q YTD Operating Income

    2Q YTD Operating Income JPY Bn 0.0 20.0 40.0 60.0 80.0 100.0 Positive Negative Factors(+) Factors(-) FY2012 Q2 Results 57.1 Daiichi Sankyo Group +33.4 Gross Profit Ranbaxy Group Gross Profit -23.9 R&D Expenses -7.7 R&D expenses: Currency Impact -12.0 Other Expenses -3.3 SG&A exc. R&D expenses: Curre

  5. Slide 5: 2Q YTD Ordinary Income / Net Income

    2Q YTD Ordinary Income / Net Income Ordinary Income JPY Bn 0 10 20 30 40 50 60 Positive Negative Factors(+) Factors(-) FY2012 Q2 Results 49.9 Operating Income -1.4 Non-operating Income: Non-operating Income +2.5 ・Ranbaxy: Forex gains on forward covers Non-operating Expenses -3.9 Non-operating Expens

  6. Slide 6: Memo

    Memo 5

  7. Slide 7: Summary of the revised FY2013 forecast

    Summary of the revised FY2013 forecast  Higher sales at Daiichi Sankyo Net  Accounting period will be changed at Ranbaxy Sales  Additional quarter Jan. – Mar. 2014 to be consolidated Operating  Decline due to exclusion of Ranbaxy’s generic Income (FTF) sales in US from the original forecast  De

  8. Slide 8: FY2013 revised consolidated forecast

    FY2013 revised consolidated forecast JPY Bn FY 2013 FY 2013 Forecast Revised Forecast change (July) (October) Net Sales 1080.0 1110.0 +30.0 (From Ranbaxy) (217.0) (224.0) (+7.0) (INR/JPY ) (1.75) (1.66) Cost of Sales 355.0 376.0 +21.0 SG&A Expenses 615.0 629.0 +14.0 R&D Expenses 187.0 191.0 +4.0 Oth

  9. Slide 9: Major Products in Japan

    Major Products in Japan Sales results and Outlook JPY Bn FY2012 FY2013 FY2013 2Q Results 2Q Results Outlook Olmetec anti-hypertension 37.6 37.6 83.0 Rezaltas anti-hypertension 8.1 9.0 21.0 analgesic and anti- Loxonin inflammatory 29.7 30.7 61.0 anti-ulcer Nexium (Proton Pump Inhibitor) 4.4 24.0 52.0

  10. Slide 10: Sales of Olmesartan (Local currency basis)

    Sales of Olmesartan(Local currency basis) USD Mn, EUR Mn JPY Bn 1,200 120.0 1,000 U.S (USD Mn) 100.0 800 80.0 Japan (JPY Bn) 600 60.0 400 40.0 EU (EUR Mn) 200 20.0 ASCA etc. (JPY Bn) 0 0.0 FY2009 FY2010 FY2011 FY2012 FY2013 Results Results Results Results Forcast Outlook Japan (JPY Bn) 77.2 87.0 94.

  11. Slide 11: FY'13 Principal management objectives

    FY’13 Principal management objectives YTD Progress update  Focus on global business profitability including Ranbaxy • Injectafer launched in Aug, • Luitpold • Shirley facility resolution efforts ongoing • Ranbaxy • US-DOJ investigation settled in May, • The group is putting best efforts to address

  12. Slide 12: Anti-platelet agent Prasugrel: Japan launch schedule

    Anti-platelet agent Prasugrel: Japan launch schedule FY2013 FY2014 Target Indications FY2015 FY2016 Oct.-Mar. Apr.-Sep. Oct.-Mar. Coronary Artery Disease undergoing Approval PCI*** Launch PRASFIT-ACS PRASFIT-Elective Ischemic Stroke Approval P3 study NDA Launch PRASTRO-I *CAD : Coronary Artery Disea

  13. Slide 13: Anti-coagulant: Edoxaban Global NDA / launch Schedule

    Anti- coagulant: Edoxaban Global NDA / launch Schedule FY2013 FY2014 Target Indications FY2015 ~ Oct.-Mar. Apr.-Sep. Oct.-Mar. Prevention of thromboembolic event in Approval atrial fibrillation NDA Launch Launch JP,US,EU ASCA JP,US,EU Acute treatment and long-term prevention of Approval Launch throm

  14. Slide 14: Contact: Corporate Communications Department

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk

Daiichi Sankyo Company — Q2 FY2013 Earnings Presentation on 6ix